Cytorex Biosciences, Inc. is a privately held Research and Development biotechnology company headquartered in Florida and R&D based in Texas with a patent pending and patented chemical technology platform with a previously unrealized approach: the use of ions and salts of acids, in the form of ions as actives. From this platform, Cytorex® can develop therapeutic agents to treat pathologies such as diverse types of cancer, autoimmune diseases, neurodegenerative diseases, kidney stones and infectious diseases caused by pathogenic microorganisms
This chemical technology platform has enabled the creation of Cytoreg®, the ionic therapy for pharmacological use. This is the result of decades of research by Professor David Martucci (our CSO and founding member) on the use of strong and weak acids and their application in pharmaceutical formulations. Cytorex Biosciences Inc. has worked on the development of new patents that have allowed the combination of salts that complement the initial technology.
Cytorex Corporation has developed a series of therapeutic candidates for the use of pharmacologically active ions in the treatment of a wide range of pathologies, including diverse types of cancer, the treatment of diabetic feet to prevent amputation, the elimination of kidney stones and, therefore, the reduction of nephritic colic, and the treatment of diseases derived from pathogenic microorganisms such as fungi, bacteria and viruses. The focus on cancer pathology, and specifically on brain tumors, is the initial focus of the efforts of Cytorex Biosciences Inc.
Preclinical studies in glioblastoma multiforme brain tumor and other types of cancer cells have demonstrated that Cytoreg® ion therapeutic technology has a high efficacy given its selectivity to target and inhibit cancer growth, as well as to induce cancer cell death by selective apoptosis. Additionally, the ionic therapeutic technology has been investigated in glioma, melanoma, breast, liver, lung, pancreatic, pituitary, prostate and testicular cancer cells, as well as in primary glioblastoma and meningioma tumors. Studies in In Vivo models have demonstrated increased blood oxygenation to facilitate wound healing, among other benefits. Hemostasis studies, in In Vivo models, show a potent hemostatic activity that allows interrupting bleeding or hemorrhage. In Vivo models, it has been demonstrated that the topical use of the therapeutic agent does not cause dermal causticity. On the other hand, in the treatment of diabetic foot, it allows healing and reduction of the effect of pathogenic microorganisms present in ulcers. In in vivo models, studies of treatment of kidney stones, have shown the reduction and disappearance of the stones quickly and thus, also eliminating the nephritic colic. In in vitro models using pathogenic microorganisms, all tests on viruses, bacteria and fungi show a rapid elimination and growth inhibition of the pathogenic microorganism and the preservation of the qualitative and quantitative activity of the cell, that is cell viability.
So, What is Cytoreg®
Cytoreg® is an ionic therapeutic technology that makes it possible to obtain different agents for pharmaceutical use. It consists of a complex carrier of ions (anions and cations) in high concentrations in a fluid that regulates mitochondrial and cellular metabolism
Pharmaceutical agents created from this ionic therapeutic technology have a low molecular weight. They are non-toxic at high concentrations.
They can be administered orally, topically and intravenously, without affecting healthy tissues or blood pH. This therapeutic technology can be used in animals and humans.